Life Sciences’ Quest for a Future-Friendly Real Estate Strategy

30 Dec 2019

Record-breaking R&D investment in the life sciences industry is spurring real estate innovation too.

Investment in new drug discovery is at an all-time high, creating opportunity and demand for more innovative real estate strategies. Last year, U.S. biopharma firms spent a record-breaking $179 billion on research and development (R&D) to improve their future pipelines, according to JLL’s Life Sciences Outlook 2019 report. And their investment is projected to grow by $34 billion by 2024, suggesting that there’s nowhere to go but up in this industry.

This investment momentum is making waves even outside the sector, with today’s life sciences industry proving a key economic driver in the U.S. After all, biotech and pharmaceutical leaders are revolutionizing the way we treat illness, with upwards of 7,000 medicines in clinical development globally and a record number of drug approvals by the FDA. And venture capital funding to the sector has also surged, growing 40 percent in the U.S. over the past year alone.

Click here to view the original article from AreaDevelopment